Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 9/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196200 | 0.86 | EPHX1 (1.00) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL8303337 | 0.85 | EPHX1 (0.77) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL14860025 | 0.85 | NPC1 (0.74) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL1604644 | 0.84 | RAB9A (1.00) | NPC1RAB9AALDH1A1KMT2AGAA | |
| SCHEMBL16108484 | 0.84 | RAB9A (1.00) | NPC1RAB9AALDH1A1KMT2AGAA | |
| SCHEMBL2351318 | 0.82 | RAB9A (0.70) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL16587394 | 0.81 | RAB9A (1.00) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL21741924 | 0.81 | NPC1 (0.68) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL8750215 | 0.81 | NPC1 (0.76) | EPHX1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL21023740 | 0.80 | EPHX1 (0.54) | EPHX1NPC1RAB9ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171810-A1 | Two Step Adhesive System | HENKEL AG & CO. KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20210163799-A1 | Two-Part, Cyanoacrylate/Free Radically Curable Adhesive Systems | HENKEL AG & CO. KGAA (DE) | 2021-06-03 | — | — | US | disclosed |
| US-10590311-B2 | Accelerators for two part curable compositions | Henkel IP & Holding GmbH (DE) | 2020-03-17 | — | — | US | disclosed |
| WO-2020035580-A1 | TWO STEP ADHESIVE SYSTEMS | Henkel IP & Holding GmbH (DE) | 2020-02-20 | — | — | WO | disclosed |
| US-9371473-B2 | Accelerators for two step adhesive systems | Henkel IP & Holding GmbH (DE) | 2016-06-21 | — | — | US | disclosed |
| US-9371473-B2 | Accelerators for two step adhesive systems | Henkel IP & Holding GmbH (DE) | 2016-06-21 | — | — | US | disclosed |
| US-9365750-B2 | Accelerators for curable compositions | Henkel IP & Holding GmbH (DE) | 2016-06-14 | — | — | US | disclosed |
| US-9365750-B2 | Accelerators for curable compositions | Henkel IP & Holding GmbH (DE) | 2016-06-14 | — | — | US | disclosed |
| US-8986847-B2 | Accelerator/oxidant/proton source combinations for two part curable compositions | Henkel IP & Holding GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8986847-B2 | Accelerator/oxidant/proton source combinations for two part curable compositions | Henkel IP & Holding GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | EPHX1 2152/4885NPC1 1260/4885RAB9A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.